Researchers at Uppsala University and Karolinska Institutet have presented a new screening approach that focuses on the identification of virus-specific morphological changes in virus-infected cells. The new method focuses on
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
Hansa Biopharma has announced that its treatment Idefirix is, as of August 1, reimbursable and available for use in the Netherlands. Idefirix is the first and only treatment approved for
The number of jobs created through Novo Nordisk Foundation grants has more than doubled in the past 5 years. In 2020, a total of 5,500 people had jobs that were
The companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2
The patent forms the basis of a new vaccine platform that the company has developed in parallel with existing platforms. The company has received a Notice of Allowance of its
Being a scientist or an entrepreneur is hard enough. Doing both at the same time sounds like an Olympic sport. Swedish scientist and “serial entrepreneur” Dr. Mathias Uhlén, PhD., professor
Anocca has announced the closing of a USD 47 million (SEK 400 million) Series B financing to further advance the company’s industrialised cellular biology platform and progress its pipeline of
Following a 70-year effort, China has been awarded a malaria-free certification from WHO. This is a notable feat for a country that reported 30 million cases of the disease annually
Aztiq Pharma Partners, a private equity fund led by Róbert Wessman, announced in the beginning of July that it has completed a 100 million USD financing to purchase a newly
SciLifeLab Group leader, Sara Mangsbo, Uppsala University, and her immunotherapeutic cancer vaccine delivery-platform, is now ready to leave the SciLifeLab Drug Discovery and Development platform (DDD). The immunotherapeutic cancer vaccine
She receives the 2021 Marie and August Krogh Prize for her dedicated efforts in cancer and immunotherapy. The Prize is awarded annually to an outstanding health researcher in Denmark. The
Imfinzi has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus
Ipsen and IRLAB have signed a licensing agreement, providing Ipsen exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist. “We are excited to enter this licensing
Forxiga has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Committee for
The COVID-19 pandemic
Vaccibody is initiating a phase 1/2, open label, dose escalation trial in healthy adult volunteers to determine safety and immunogenicity of two SARS CoV-2 virus DNA vaccine candidates. Vaccibody’s development
A new study has revealed that the second dose of the Pfizer-BioNTech COVID-19 vaccine triggers massive immune response against the virus. Researchers at the Stanford University School of Medicine, US,
A Danish research team has developed a new and more rapid test method that determines whether a person’s antibodies continue to protect them – also against new variants. The test
SynAct Pharma has announced additional results from all treated patients in the Phase 2a clinical trial of AP1189 in Covid-19 infected patients with pulmonary insufficiency. The study was setup with
Real-world data from Canada showed 82% and 87% effectiveness after one dose against hospitalization or death caused by Beta/Gamma and Delta variants respectively. Results from the Canadian Immunization Research Network
A new study from Umeå University shows that a first dose of AstraZeneca’s COVID-19 vaccine and a second dose of an mRNA COVID-19 vaccine gives a good immune response against
A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a
Drug and device development
Ultimovacs has announced that its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, demonstrated a 60% objective response rate (ORR) in metastatic malignant melanoma. All patients have
The US Food and Drug Administration, FDA, has issued a safety alert to patients and health care professionals, regarding an increased risk of death associated with Pepaxto (melphalan flufenamide), in
The company has presented data showing that an investigational 2.0 mg dose of Ozempic provided statistically significant and superior reductions in blood sugar compared with Ozempic 1.0 mg. These data
The company has received CE mark approval for a neuromodulation treatment of Chronic Migraine. The Swedish company’s existing EC-certificate for K.O.S has now been granted an extension with the indication
Oncopeptides has announced updated results and safety measures based on the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in
Profile
Driven by the curiosity of nature’s secrets, Jennifer Doudna, Nobel Laureate in Chemistry 2020, has devoted her life to the mysteries of biochemistry and cracking a game-changing code. Jennifer Doudna’s
In a new job
The pandemic has led to several changes in our working lives, including new digital tools, new kinds of offices and more work-life balance. But it has also meant loss of
Medivir has announced that Yilmaz Mahshid leaves the position as CEO of Medivir. The nomination committee proposes that he is elected as Board Member of the company and that Uli
Tarek Samad will join Lundbeck on 1 May 2021 as Senior Vice President, Head of Research. Samad will play a key role in Lundbeck’s ambition to have a premier neuroscience
Careers
For some people, testing the same thing over and over – tweaking, refining and then trying again – would seem tedious. For Charlotte Aagaard, however, trial-and-error to obtain final results
Read the latest issue of our magazine!
No 02 2021 // As an example of the versatility of the Nordic life science industry we have chosen to highlight five Nordic stars in this issue; five companies at different stages of development, with different focus areas, from different Nordic countries, representing the different strongholds that the region possesses.
Our profile in this issue, Mathias Uhlén, is also a great example of a Nordic life science star, dedicated to both science and entrepreneurship he has put Sweden, and the Nordic region, on the global life science map. We have also taken a closer look at remote work (is this the new ”normal”?), Mariana Dalarsson, a women in science award recipient, shares her career advice, and much more!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
This one day live and virtual event provides insights and future trends aiming to inspire and stimulate fruitful collaborations. The event gathers representatives from industry, academia, and the healthcare sector
The Swedish-American Life Science Summit (SALSS) 2021 will take place in Stockholm, Sweden, on October 20-22. The focus on the event will be cell and gene therapy and a crucial
Outsourcing in Clinical Trials & Clinical Trial Supply Nordics – This event gathers the pharmaceutical, biotechnology, and medical device communities to discuss strategies for operational success in clinical trials. With
The latest research news from the Nordic region
Science Article
Researchers at Uppsala University and Karolinska Institutet have presented a new screening approach that focuses on the identification of virus-specific morphological changes in virus-infected cells. The new method focuses on
Piece by piece the Nobel Laureates laid the puzzle in understanding and determining the hepatitis C virus, a discovery that has saved millions of lives. The Nobel Prize in Physiology
She receives the 2021 Marie and August Krogh Prize for her dedicated efforts in cancer and immunotherapy. The Prize is awarded annually to an outstanding health researcher in Denmark. The
Mariana Dalarsson, a L’Oréal-Unesco For Women in Science in Sweden 2021 award recipient, has an interdisciplinary approach to fighting cancer. The L’Oréal-Unesco For Women in Science in Sweden honors outstanding
The patient, suffering from retinitis pigmentosa, is a participant in the ongoing PIONEER Phase I/II clinical trial of GenSight Biologics’ GS030 optogenetic therapy. These groundbreaking results, from among others biopharma
New molecules, developed by researchers at Linköping University, have promising properties as possible drugs against epilepsy. A study published in the journal Epilepsia shows that several of the molecules have
Nordic Life Science
The latest clinical trials
The US Food and Drug Administration, FDA, has issued a safety alert to patients and health care professionals, regarding an increased risk of death associated with Pepaxto (melphalan flufenamide), in
The company has presented data showing that an investigational 2.0 mg dose of Ozempic provided statistically significant and superior reductions in blood sugar compared with Ozempic 1.0 mg. These data
The company has received CE mark approval for a neuromodulation treatment of Chronic Migraine. The Swedish company’s existing EC-certificate for K.O.S has now been granted an extension with the indication
Oncopeptides has announced updated results and safety measures based on the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in
Cantargia has announced that the development of nadunolimab (CAN04) has been broadened following the submission of an application of a phase I/II clinical trial to evaluate combination with chemotherapy in
The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their
XNK Therapeutics has announced that the first patient has been included in a Phase II clinical study to treat patients with Multiple myeloma using XNK’s autologous natural killer (NK) cell-based
The company announces that the first patient has been enrolled in study evaluating the efficacy of digital therapeutic modia in combination with sublingual buprenorphine/ naloxone for the treatment of opioid
Follicum reports revised data from a Phase IIa study of the tissue repairing peptide FOL-005 for the treatment of hair loss (alopecia). The revised data are based on an independent
Sign up to our newsletter